WALID M. AWNI,MENON RAJEEV M.,WEI LIU,DUTTA SANDEEP,BARRY M. BERNSTEIN,THOMAS J. PODSADECKI,ANDREW L. CAMPBELL,LIN CHIH-WEI,WANG TIANLI
申请号：
NZ63115514
公开号：
NZ631155A
申请日:
2014.03.14
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is the use of at least two direct acting antiviral agents (DAAs) for the manufacture of a medicament or medicaments for treatment of Hepatitis C virus (HCV) in an HCV patient, wherein in said treatment said at least two DAAs are administered to said patient and wherein neither interferon nor ribavirin are administered to said patient during said treatment, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise: Compound 1 or a pharmaceutically acceptable salt thereof, and Compound 2 or a pharmaceutically acceptable salt thereof.
